FDA staff question efficacy of Vertex experimental CF drug in combination

(Reuters) - FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease.Read more...